Please wait while we open this resource.
K
Clinical reviews
PRASUGREL VERSUS TICAGRELOR IN ACUTE CORONARY SYNDROMES
University of Gothenburg
PDF20269 pages223 KB
The study investigates whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients experiencing acute coronary syndromes. It involves a randomized trial conducted in Sweden, where regions switched from ticagrelor to prasugrel as the default treatment. The primary endpoint includes a composite of death, myocardial infarction, or stroke over one year, assessed through national registries.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology